Biotechnology

The biotechnology industry converts biological research into approved medical products through a multi-stage development process spanning preclinical research, clinical trials, regulatory review, and manufacturing scale-up. The defining structural characteristic is the length, cost, and uncertainty of this pipeline: a typical drug candidate requires over a decade of development, with attrition rates exceeding 90% across clinical phases, meaning most invested capital yields no commercial product.

This risk profile shapes the capital structure of the industry. Pre-revenue companies fund development through equity issuance, venture capital, and licensing partnerships, relying on external capital willingness to accept binary outcomes. Once products reach market, revenue dynamics depend on pricing, payer reimbursement, physician adoption, and competitive alternatives, all within the finite window of patent-protected exclusivity before biosimilar entry erodes pricing.

Manufacturing biological products requires specialized facilities with stringent quality controls and cold-chain logistics, adding capital and operational complexity beyond the research and approval stages. Regulatory oversight governs the entire lifecycle from development through post-market surveillance, creating a persistent compliance infrastructure requirement that scales with the number of approved products and active clinical programs.